Yang Hsuan-Chia, Chou Wen-Chi, Nguyen Phung-Anh, Nguyen Nhi Thi Hong, Phuong Nguyen Thi, Wang Ching-Huan, Hsu Jason C, Lin Ming-Chin, Huang Chih-Wei
Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
International Center for Health Information Technology (ICHIT), College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Cancer Sci. 2025 Mar;116(3):783-791. doi: 10.1111/cas.16422. Epub 2024 Dec 4.
Pancreatic cancer is among the deadliest cancers, with a grim prognosis despite advances in treatment. We conducted a population-based case-control study from Taiwan, linking Health and Welfare Data Science Center data to the Taiwan Cancer Registry, which offers a promising strategy for its treatment through drug repurposing. The study aims to identify the association of anti-parkinsonian drugs with pancreatic cancer risk across different age groups. The analysis encompassed 18,921 pancreatic cancer cases and 75,684 matched controls, employing conditional logistic regression to assess the impact of anti-parkinsonian drugs on the risk of pancreatic cancer. Key findings revealed a statistically significant association of the administration with specific anti-parkinsonian medications, including anticholinergic agents, tertiary amines, dopa derivatives, and dopamine receptor agonists, with a reduction in pancreatic cancer risk. These associations were represented as adjusted odds ratios (aORs), ranging from 0.620 (95% CI 0.470-0.810) to 0.764 (95% CI 0.655-0.891). Further, age-stratified analysis revealed variations in efficacy across different age groups. Anticholinergic agents and tertiary amines exhibited greater effectiveness in the 40-64-year age group (aOR, 0.653; 95% CI, 0.489-0.872), whereas dopa derivatives and dopamine receptor agonists were particularly efficacious in the cohort aged ≥65 years (aOR, 0.728; 95% CI, 0.624-0.850 and aOR, 0.665; 95% CI, 0.494-0.894, respectively). Notably, specific drugs such as trihexyphenidyl, levodopa/dopa decarboxylase inhibitor (DDCI), and pramipexole demonstrated a significant decrease in cancer risk, especially in the elderly population. These preliminary findings can contribute to the possible therapeutic role of anti-parkinsonian drugs in the treatment of pancreatic cancer.
胰腺癌是最致命的癌症之一，尽管治疗有所进展，但预后仍不容乐观。我们在台湾进行了一项基于人群的病例对照研究，将卫生福利数据科学中心的数据与台湾癌症登记处相链接，这为通过药物重新利用来治疗胰腺癌提供了一种有前景的策略。该研究旨在确定不同年龄组中抗帕金森药物与胰腺癌风险之间的关联。分析纳入了18921例胰腺癌病例和75684例匹配对照，采用条件逻辑回归来评估抗帕金森药物对胰腺癌风险的影响。主要研究结果显示，使用特定抗帕金森药物（包括抗胆碱能药物、叔胺类、多巴衍生物和多巴胺受体激动剂）与胰腺癌风险降低之间存在统计学上的显著关联。这些关联以调整后的比值比（aOR）表示，范围从0.620（95%可信区间0.470 - 0.810）到0.764（95%可信区间0.655 - 0.891）。此外，年龄分层分析显示不同年龄组的疗效存在差异。抗胆碱能药物和叔胺类在40 - 64岁年龄组表现出更大的疗效（aOR，0.653；95%可信区间，0.489 - 0.872），而多巴衍生物和多巴胺受体激动剂在≥65岁的队列中特别有效（aOR分别为0.728；95%可信区间，0.624 - 0.850和aOR，0.665；95%可信区间，0.494 - 0.894）。值得注意的是，诸如苯海索、左旋多巴/多巴脱羧酶抑制剂（DDCI）和普拉克索等特定药物显示出癌症风险显著降低，尤其是在老年人群中。这些初步研究结果有助于揭示抗帕金森药物在胰腺癌治疗中可能的治疗作用。
